Goldman Sachs
NMTC icon

Goldman Sachs’s NeuroOne Medical Technologies NMTC Stock Holding History

Goldman Sachs’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,461
Closed -$20.3K – 6828
2025
Q4 		$20.3K Buy
+4,461
New +$20.3K ﹤0.01% 6342
2025
Q2 		– Sell
-16,429
Closed -$83.8K – 6313
2025
Q1 		$83.8K Buy
+16,429
New +$104K ﹤0.01% 5821

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Goldman Sachs's NMTC Position: Q1 2026 in Review

Goldman Sachs sold out of NeuroOne Medical Technologies (NMTC) in Q1 2026, closing a stake of 4,461 shares — an estimated $20.3K sold.

Goldman Sachs first reported a position in NMTC in Q1 2025 and held it in 2 quarters. The position peaked at $83.8K in Q1 2025. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Goldman Sachs reported no remaining NeuroOne Medical Technologies position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 4,461 NeuroOne Medical Technologies shares in Q1 2026, an estimated $20.3K.
  • Goldman Sachs first reported a position in NeuroOne Medical Technologies in Q1 2025 and held it in 2 quarters.
  • Goldman Sachs's NeuroOne Medical Technologies position peaked at $83.8K in Q1 2025.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.